DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)

被引：0
|
作者：
Park, S. H. [1 ]
Castellano, D. [2 ]
Petrylak, D. P. [3 ]
Galsky, M. D. [4 ]
van der Heijden, M. S. [5 ]
Loriot, Y. [6 ]
Ogawa, O. [7 ]
Su, W-P. [8 ]
Huang, W. [9 ]
Levin, W. [9 ]
Ferro, S. [9 ]
Ben, Y. [9 ]
Bellmunt, J. [10 ]
Powles, T. [11 ]
机构：
[1] Samsung Med Ctr, Dept Med, Seoul, South Korea
[2] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[3] Yale Univ, Dept Med, New Haven, CT 06520 USA
[4] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[5] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[6] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[7] Kyoto Univ, Dept Urol, Kyoto, Japan
[8] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[9] AstraZeneca, Global Med Dev, Gaithersburg, MD USA
[10] Harvard Med Sch, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA
[11] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med Ctr, London, England
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
285TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
    Rizvi, Naiyer A.
    Cho, Byoung Chul
    Reinmuth, Niels
    Lee, Ki Hyeong
    Luft, Alexander
    Ahn, Myung-Ju
    van den Heuvel, Michel M.
    Cobo, Manuel
    Vicente, David
    Smolin, Alexey
    Moiseyenko, Vladimir
    Antonia, Scott J.
    Le Moulec, Sylvestre
    Robinet, Gilles
    Natale, Ronald
    Schneider, Jeffrey
    Shepherd, Frances A.
    Geater, Sarayut Lucien
    Garon, Edward B.
    Kim, Edward S.
    Goldberg, Sarah B.
    Nakagawa, Kazuhiko
    Raja, Rajiv
    Higgs, Brandon W.
    Boothman, Anne-Marie
    Zhao, Luping
    Scheuring, Urban
    Stockman, Paul K.
    Chand, Vikram K.
    Peters, Solange
    JAMA ONCOLOGY, 2020, 6 (05) : 661 - 674
  • [22] BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).
    Rosenberg, Jonathan E.
    Park, Se Hoon
    Dao, Tu V.
    Castellano, Daniel E.
    Li, Jian-Ri
    Mukherjee, Som
    Howells, Kathryn
    Dry, Hannah
    Lanasa, Mark C.
    Stewart, Ross
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [23] A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
    Abou-Alfa, Ghassan K.
    Chan, Stephen Lam
    Furuse, Junji
    Galle, Peter R.
    Kelley, Robin Kate
    Qin, Shukui
    Armstrong, Jon
    Darilay, Annie
    Vlahovic, Gordana
    Negro, Alejandra
    Sangro, Bruno
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study
    Mamdani, Hirva
    Kim, Seongho
    Gentzler, Ryan D.
    Shields, Misty Dawn
    Furqan, Muhammad
    Pizana, Kristen
    Abid, Qura
    Jalal, Shadia Ibrahim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011
    Loriot, Yohann
    Balar, Arjun Vasant
    De Wit, Ronald
    Garcia, Jorge A.
    Grivas, Petros
    Matsubara, Nobuaki
    Moreno, Blanca Homet
    Sbar, Eric
    Jia, Xieyang Calvin
    Dutcus, Corina E.
    Siefker-Radtke, Arlene O.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial (vol 21, pg 1574, 2020)
    Powles, T.
    van der Heijden, M. S.
    Castellano, D.
    LANCET ONCOLOGY, 2021, 22 (01): : E5 - E5
  • [27] A phase 3, randomized, open-label study of first-line durvalumab (MED14736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.
    Seiwert, Tanguy Y.
    Weiss, Jared
    Baxi, Shrujal S.
    Ahn, Myung-Ju
    Fayette, Jerome
    Gillison, Maura L.
    Machiels, Jean-Pascal H.
    Takahashi, Shunji
    Melillo, Giovanni
    Franks, April
    Emeribe, Ugochi
    Raben, David
    McDevitt, Michael
    Psyrri, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
    Galsky, Matt D.
    Powles, Thomas
    Li, Shengting
    Hennicken, Delphine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] IMPACT OF PLATINUM AGENT [CISPLATIN (CIS) OR CARBOPLATIN (CA)] IN FIRST-LINE CHEMOTHERAPY (CT) ON OVERALL SURVIVAL IN METASTATIC UROTHELIAL CARCINOMA (MUC) PATIENTS (PTS): A RETROSPECTIVE STUDY
    Auvray, M.
    Vano, Y.
    Combe, P.
    Elaidi, R.
    Auclin, E.
    Takouchop, C.
    Medioni, J.
    Scotte, F.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [30] A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian
    Paz-Ares, Luis G.
    Jiang, Haiyi
    Huang, Yifan
    Dennis, Phillip A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345